NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Receipt of Positive Nasdaq Listing DeterminationPRNewsWire • 01/17/24
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and PyelonephritisPRNewsWire • 01/16/24
NRx Pharmaceuticals (Nasdaq: NRXP) to Present Keynote Address on Ketamine Efficacy and Risks at Upcoming Sachs Neuroscience Innovation Forum in San FranciscoPRNewsWire • 01/02/24
NRx Pharmaceuticals (Nasdaq: NRXP) Demonstrates Compliance with Nasdaq MVLS StandardPRNewsWire • 01/02/24
NRx Pharmaceuticals Announces the Election of Janet Rehnquist to its Board of DirectorsPRNewsWire • 12/27/23
NRx Pharmaceuticals Announces Signing of a Data and Technical Information Agreement with Columbia University Accessing Key Data Demonstrating Efficacy and Safety of Intravenous Ketamine for the Treatment of Suicidal DepressionPRNewsWire • 12/19/23
NRx Pharmaceuticals Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract InfectionsPRNewsWire • 12/18/23
NRx Pharmaceuticals to Present at Noble Capital Markets' 19th Annual Emerging Growth Investor ConferencePRNewsWire • 11/27/23
NRx Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdatePRNewsWire • 11/13/23
NRx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 14, 2023PRNewsWire • 11/07/23
NRx Pharmaceuticals and Nephron Pharmaceuticals Announce Joint Agreement to Develop Intravenous Ketamine to Treat Suicidal DepressionPRNewsWire • 11/06/23
NRx Pharmaceuticals Announces Signing of a Development Agreement for the Manufacture of Ketamine to Treat Suicidality and DepressionPRNewsWire • 10/31/23
NRx Pharmaceuticals Announces Further Alignment with FDA on Initiation of Registrational Trials for NRX-101 in the Treatment of Chronic PainPRNewsWire • 10/26/23
NRx Pharmaceuticals Announces Strategic Change in Development of NRX-100 (IV Ketamine) at Dawson James Small Cap Investor ConferencePRNewsWire • 10/12/23
NRx Pharma (NRXP) to Initiate Clinical Study on NRX-101, Stock UpZacks Investment Research • 10/03/23
NRx Pharmaceuticals Announces FDA Permission to Proceed on Investigational New Drug (IND) Application for NRX-101 to Treat Chronic PainPRNewsWire • 10/02/23